Phase I Study of TQB2922 Subcutaneous Injection to Assess Safety and Drug Behavior in Adults With Advanced Non-Squamous Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the safety and how the body processes TQB2922, a bispecific antibody given by injection under the skin, in adults with advanced cancers. This Phase I study focuses on patients with advanced non-squamous non-small cell lung cancer who have measurable tumors that are progressing despite prior treatment or lack effective options. The trial is sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Participants will receive TQB2922 injections in treatment cycles lasting 28 days. The study includes detailed monitoring of the drugs levels in the blood at multiple time points during and after dosing across several cycles to understand its behavior in the body. The treatment continues through multiple cycles while patients are observed for side effects and response. Participants will have frequent blood draws and evaluations during the study to measure drug concentration and pharmacokinetics, including peak levels and how long the drug stays in the body. Safety will be monitored by recording adverse events up to 30 days after the last dose. Researchers will also assess cancer response and progression over up to three years. The total study duration may extend with follow-up to observe long-term effects and immune responses to the drug.

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers